Pharmacology, Toxicology and Pharmaceutical Science
Acute Kidney Failure
5%
Adverse Drug Reaction
31%
Adverse Event
6%
Anticoagulant Agent
100%
Antivitamin K
47%
Apixaban
12%
Artery Thrombosis
10%
Atrial Fibrillation
25%
Bleeding
40%
Brain Hemorrhage
5%
Cause of Death
7%
Clinical Study
25%
Cohort Study
25%
Complication
5%
Dabigatran
38%
Dabigatran Etexilate
25%
Daboia russellii
25%
Direct Oral Anticoagulant
49%
Diseases
18%
Drug
11%
Drug Approval
12%
Drug Concentration
29%
Drug Interaction
15%
Eculizumab
30%
Emergency
6%
Ensure
12%
Flow Cytometry
7%
Gastrointestinal Hemorrhage
5%
Hemolysis
13%
Hypertension
5%
Infection
5%
Kidney Failure
11%
Life Expectancy
5%
Myelodysplastic Syndrome
5%
Paroxysmal Nocturnal Hemoglobinuria
76%
Pathophysiology
30%
Pharmacodynamics
11%
Pharmacokinetics
5%
Phospholipid
8%
Prevalence
12%
Procoagulant
25%
Prospective Study
50%
Rivaroxaban
63%
Thrombin
11%
Thromboembolism
50%
Thrombosis
25%
Toxic Injury
17%
Transient Ischemic Attack
6%
Vein Thrombosis
10%
Viper Venom
25%
Medicine and Dentistry
Acquired Disorder
10%
Acute Promyelocytic Leukemia
12%
Analysis
5%
Aplastic Anemia
5%
Artery Thrombosis
10%
Assay
38%
Cause of Death
5%
Cells
25%
Complication
9%
Diagnosis
50%
Disease
5%
Disseminated Intravascular Coagulation
6%
Donor
5%
Dystonia
5%
Erythrocyte
17%
Erythrocyte Concentrate
50%
Flow Cytometry
9%
Hematopoietic Stem Cell
10%
Hemolysis
14%
Heparin
25%
Heparin-Induced Thrombocytopenia
25%
Hypertension
5%
In Vitro
5%
Infection
5%
Kidney Function
5%
Laboratory
5%
Leukemia Cell
6%
Membrane Microparticle
25%
Microparticle
25%
Monocyte
5%
Paroxysmal Nocturnal Hemoglobinuria
50%
Pathophysiology
30%
Patient
22%
Patient Experience
10%
Phlebothrombosis
10%
Phospholipid
14%
Platelet Microparticle
25%
Procoagulant
47%
Prophylaxis
10%
Pulmonary Hypertension
5%
Release Assay
11%
Renal Failure
5%
Serotonin Release
11%
Smooth Muscle
5%
Therapeutic Procedure
30%
Thrombin
20%
Thromboplastin
25%
Thrombosis
25%
Transfusion
10%
Venous Thromboembolism
12%
Nursing and Health Professions
Analyzer
19%
Anticoagulant Agent
27%
Anticoagulation
25%
Antivitamin K
21%
Blood Level
8%
Clinical Outcome
14%
Cohort Analysis
25%
Combination Therapy
12%
Control
6%
Dabigatran
25%
Eculizumab
25%
Erythrocyte Concentrate
25%
Erythrocyte Preservation
5%
Experiment
6%
Flow Cytometry
6%
Heparin Induced Thrombocytopenia
25%
Laboratory
6%
Liquid Chromatography-Mass Spectrometry
8%
Low Molecular Weight Heparin
6%
Parameters
6%
Paroxysmal Nocturnal Hemoglobinuria
25%
Pathophysiology
25%
Patient
25%
Procoagulant
9%
Release Assay
11%
Reproducibility
6%
Rivaroxaban
25%
Sample
33%
Serotonin
11%
Standardization
6%
Temperature
6%
Thrombin
25%
Thrombocyte Free Plasma
9%
Time
31%
Trough Concentration
8%
Viper Venom
25%